Title:
ＧＩＰおよびＧＬＰ−１コアゴニスト化合物
Document Type and Number:
Japanese Patent JP6754867
Kind Code:
B2
Abstract:
The present invention relates to dual incretin peptide mimetic compounds that agonize receptors for both human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and may be useful for treating type 2 diabetes mellitus (T2D).
Inventors:
Arcina-Fernandez, Giorgi
Bokvist, Bent Christer
Koscoon, Tamar
Cummins, Robert Chadwick
Bokvist, Bent Christer
Koscoon, Tamar
Cummins, Robert Chadwick
Application Number:
JP2019113638A
Publication Date:
September 16, 2020
Filing Date:
June 19, 2019
Export Citation:
Assignee:
Eli Lilly and Company
International Classes:
A61K38/26; A61K31/155; A61K31/17; A61K31/425; A61K45/00; A61K47/18; A61K47/54; A61P3/04; C07K14/605
Domestic Patent References:
| JP2008528659A | ||||
| JP2011509077A |
Foreign References:
| WO2013164483A1 | ||||
| WO2014192284A1 | ||||
| WO2011119657A1 | ||||
| WO2012088379A1 | ||||
| WO2013192129A1 |
Other References:
Current Pharmaceutical Design (2004) Vol.10, No.29, pp.3651-3662
Diabetes, Obesity and Metabolism (2011) Vol.13, pp.19-25
Diabetologia (1998) Vol.41, pp.271-278
Diabetes, Obesity and Metabolism (2011) Vol.13, pp.19-25
Diabetologia (1998) Vol.41, pp.271-278
Attorney, Agent or Firm:
Hiroshi Kobayashi
Eiji Katayama
Norio Omori
Hakoda Mitsuru
Yasuhito Suzuki
Eiji Katayama
Norio Omori
Hakoda Mitsuru
Yasuhito Suzuki